136117-69-6

Basic information

• Product Name: METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE
• Synonyms: METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE;Methyl imidazo[1,2-a]pyri...;IMidazo[1,2-a]pyridine-6-carboxylic acid, Methyl ester;Methyl iMidazo[1,2-a]pyridin-6-carboxylate;6-imidazo[2,1-f]pyridinecarboxylic acid methyl ester;imidazo[2,1-f]pyridine-6-carboxylic acid methyl ester;methyl imidazo[2,1-f]pyridine-6-carboxylate;methyl H-imidazo1,2-apyridine-6-carboxylate
• CAS NO: 136117-69-6
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17
• Product Categories: pharmacetical;Esters;Fused Ring Systems
• Mol File: 136117-69-6.mol

Chemical Properties

• Melting Point: 147-148°C
• Appearance: /
• Density: 1.26 g/cm³
• Refractive Index: 1.607
• PKA: 5.18±0.50(Predicted)
• CAS DataBase Reference: METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE(136117-69-6)
• EPA Substance Registry System: METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE(136117-69-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 136117-69-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE is used as a building block for the creation of new drugs and therapeutic agents, leveraging its potential biological activities and unique chemical structure to develop innovative treatments.
Used in Organic Synthesis:
In the field of organic synthesis, METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE is utilized as a key intermediate, contributing to the synthesis of complex organic molecules and compounds with specific properties and applications.
Used in Antimicrobial Applications:
METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE is employed as an antimicrobial agent, harnessing its potential to combat various microorganisms and contributing to the development of new antibiotics and antimicrobial therapies.
Used in Anti-inflammatory Applications:
METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE is used as an anti-inflammatory agent, capitalizing on its ability to modulate inflammatory responses and potentially leading to the development of novel treatments for inflammatory diseases.
Used in Antitumor Applications:
METHYL IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLATE is utilized in antitumor research, exploring its potential to inhibit tumor growth and progression, and contributing to the advancement of cancer therapies.

InChI:InChI=1/C9H8N2O2/c1-13-9(12)7-2-3-8-10-4-5-11(8)6-7/h2-6H,1H3

Upstream product

• 36052-24-1 methyl 6-aminonicotinoate 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 107-20-0 2-chloroethanal 
• 4360-63-8 2-bromomethyl-1,3-dioxolane 
• 67-56-1 methanol 
• 139022-25-6 imidazo[1,2-a]pyridine-6-carboxylic acid 
• 74-88-4 methyl iodide 
• 17157-48-1 bromoacetaldehyde 

Downstream Products

• 116355-16-9 6-imidazo<1,2-a>pyridinecarboxaldehyde 
• 886361-97-3 imidazo[1,2-a]pyridine-6-carbohydrazide 
• 886361-98-4 3-bromoimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester 
• 139183-98-5 methyl 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate 
• 886362-00-1 3-bromoimidazo[1,2-a]pyridine-6-carboxylic acid 
• 1313725-89-1 (R)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine 
• 1313725-88-0 savolitinib 
• 944905-12-8 1-(imidazo[1,2-a]pyridin-6-yl)ethanone 
• 1270475-03-0 1-(imidazo[1,2-a]pyridin-6-yl)ethanamine 
• 103313-38-8 imidazo[1,2-a]pyridine-6-carboxamide 
• 132213-07-1 6-(hydroxymethyl)imidazo[1,2-a]pyridine 
• 948883-29-2 3-imidazo[1,2-a]pyridin-6-yl-3-oxo-propionitrile 
• 106730-54-5 olprinone 
• 139022-25-6 imidazo[1,2-a]pyridine-6-carboxylic acid 

Relevant articles and documents

Discovery of (S)-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

Fragment based discovery of a novel and selective PI3 kinase inhibitor

We report the use of fragment screening and fragment based drug design to develop a PI3c kinase fragment hit into a lead. Initial fragment hits were discovered by high concentration biochemical screening, followed by a round of virtual screening to identify additional ligand efficient fragments. These were developed into potent and ligand efficient lead compounds using structure guided fragment growing and merging strategies. This led to a potent, selective, and cell permeable PI3c kinase inhibitor with good metabolic stability that was useful as a preclinical tool compound.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

ORGANIC COMPOUNDS

Compounds of formula (I): in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treati ng diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical composit ions that contain the compounds and processes for preparing the compounds are also described.

SYNTHESIS OF PYRAZOLES

The present invention provides methods of making HCl salts, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Retinoid x receptor modulators

The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

Synthesis and biological evaluation of 2-Indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent

A series of indole containing oxazolines has been discovered as a result of structural modifications of the lead compound A-105972. The compounds exert their anticancer activity through inhibition of tubulin polymerization by binding at the colchicine site. A-289099 was identified as an orally active antimitotic agent active against various cancer cell lines including those that express the MDR phenotype. The anticancer activity, pharmacokinetics, and an efficient and enantioselective synthesis of A-289099 are described.